
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a global biopharmaceutical holding company that primarily generates revenue from the sales of its oncology-focused portfolio of products. Their recent 1Q26 results, which included a topline beat and a raise in guidance, showcase the strength of their lead product, BRUKINSA, and its continued outpacing of competitors in market share. With potential near-term approvals for sonrotoclax in r/r MCL and BGB-16673 in r/r CLL, as well as updates on other promising programs, BeOne Medicines has a strong pipeline and a clearer path to future value and potential inflection points. However, risks include product commercial and supply chain issues, competition, and legal and regulatory hurdles.
Bears say
BeOne Medicines is facing strong competition in the oncology market and is highly reliant on the success of their drug Brukinsa, which currently makes up the majority of their revenue. While the company has shown strong growth in recent years, there is a risk that their pipeline may not fully deliver, as evidenced by delays in their BTK degrader drug. Furthermore, the high level of expenses for research and development and marketing, combined with a potential near-term commercial opportunity in the post-BTKi/post-BCL2i CLL setting, may put a strain on their financials and growth potential.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares